LOS ANGELES, March 4, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 11, 2020 and November 4, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before April 13, 2021.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Bluebird presented insufficient data to support its U.S. Biologics Licensing Application ("BLA") submission for LentiGlobin for sickle cell disease ("SCD"). The Company downplayed the risk of disruptions related to the COVID-19 pandemic to its BLA submission schedule for LentiGlobin for SCD, especially on the topic of manufacturing. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about bluebird, investors suffered damages.